Melanoma Clinical Trial

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Summary

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
At least 1 lesion accessible for biopsy
Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
Participants with active, known or suspected autoimmune disease
Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

281

Study ID:

NCT03400332

Recruitment Status:

Active, not recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 72 Locations for this study

See Locations Near You

Local Institution - 0059
Springdale Arkansas, 72762, United States
Local Institution - 0099
Los Angeles California, 90033, United States
Local Institution - 0007
Lakewood Colorado, 80228, United States
Local Institution - 0087
Atlanta Georgia, 30322, United States
Local Institution - 0100
Atlanta Georgia, 30342, United States
Local Institution - 0101
Marietta Georgia, 30060, United States
Local Institution - 0012
Columbia Maryland, 21044, United States
Local Institution - 0003
Lutherville Maryland, 21093, United States
Local Institution - 0060
Boston Massachusetts, 02215, United States
Local Institution - 0004
Ann Arbor Michigan, 48109, United States
Local Institution - 0076
Omaha Nebraska, 68130, United States
Comprehensive Cancer Centers Of Nevada
Las Vegas Nevada, 89169, United States
Local Institution - 0005
Hackensack New Jersey, 07601, United States
Local Institution - 0032
New Brunswick New Jersey, 08903, United States
Local Institution - 0025
New York New York, 10029, United States
Local Institution - 0002
New York New York, 10032, United States
Local Institution - 0028
Oklahoma City Oklahoma, 73104, United States
Local Institution - 0017
Eugene Oregon, 97401, United States
Local Institution - 0001
Pittsburgh Pennsylvania, 15213, United States
Local Institution - 0009
Greenville South Carolina, 29615, United States
Local Institution - 0011
Austin Texas, 78705, United States
Local Institution - 0010
Dallas Texas, 75246, United States
Local Institution - 0014
Fort Worth Texas, 76104, United States
Local Institution - 0018
Houston Texas, 77030, United States
Local Institution - 0006
San Antonio Texas, 78240, United States
Local Institution - 0013
Tyler Texas, 75702, United States
Local Institution - 0058
Salt Lake City Utah, 84112, United States
Local Institution - 0015
Fairfax Virginia, 22031, United States
Local Institution - 0008
Norfolk Virginia, 23502, United States
Local Institution - 0088
Wollstonecraft New South Wales, 2065, Australia
Local Institution - 0096
Adelaide South Australia, 5000, Australia
Local Institution - 0090
Melbourne Victoria, 3000, Australia
Local Institution - 0095
Melbourne Victoria, 3004, Australia
Local Institution - 0097
Perth Western Australia, 6009, Australia
Local Institution - 0091
Ballarat Central , VIC 3, Australia
Local Institution - 0037
Bruxelles , 1200, Belgium
Local Institution - 0036
Gent , 9000, Belgium
Local Institution - 0082
Kortrijk , 8500, Belgium
Local Institution - 0030
Edmonton Alberta, T6G 1, Canada
Local Institution - 0029
Vancouver British Columbia, V5Z 4, Canada
Local Institution - 0078
Victoria British Columbia, V8R 6, Canada
Local Institution - 0020
Toronto Ontario, M5G 1, Canada
Local Institution - 0055
Toronto Ontario, M5G 2, Canada
Local Institution - 0056
Montréal Quebec, H2X 0, Canada
Local Institution - 0067
Marseille Bouches-du-Rhône, 13385, France
Local Institution - 0085
Nantes , 44000, France
Local Institution - 0068
Paris , 75010, France
Local Institution - 0102
Toulouse , 31059, France
Local Institution - 0069
Villejuif , 94800, France
Local Institution - 0054
Tübingen Baden-Württemberg, 72076, Germany
Local Institution - 0052
Mainz Rheinland-Pfalz, 55131, Germany
Local Institution - 0034
Berlin , 12200, Germany
Local Institution - 0053
Hamburg , 20251, Germany
Local Institution - 0043
Forlì , 47014, Italy
Local Institution - 0042
Milano , 20132, Italy
Local Institution - 0027
Napoli , 80131, Italy
Local Institution - 0026
Rozzano-milano , 20089, Italy
Local Institution - 0071
Krakow , 31-11, Poland
Local Institution - 0077
Warszawa , 02-78, Poland
Local Institution - 0045
Madrid , 28034, Spain
Local Institution - 0022
Madrid , 28040, Spain
Local Institution - 0023
Madrid , 28050, Spain
Local Institution - 0044
Malaga , 29010, Spain
Local Institution - 0021
Pamplona , 31008, Spain
Local Institution - 0047
Santiago de Compostela , 15706, Spain
Local Institution - 0049
Lund , 221 8, Sweden
Local Institution - 0040
Lausanne , 1011, Switzerland
Local Institution - 0041
St.Gallen , 9007, Switzerland
Local Institution - 0039
Zuerich , 8091, Switzerland
Local Institution - 0024
Manchester Greater Manchester, M20 4, United Kingdom
Local Institution - 0083
Glasgow Lanarkshire, G12 0, United Kingdom
Local Institution - 0019
Birmingham West Midlands, B15 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

281

Study ID:

NCT03400332

Recruitment Status:

Active, not recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider